Dr. Scully was the lead author of the HERCULES study. The objective of the Phase 3 study pre approval was to evaluate the long term-safety and efficacy of repeated use of caplacizumab (Cablivi® ) and to characterize long term impact of TTP. TTP is a rare, life...